Navigation Links
Interleukin Genetics Reports Third Quarter 2011 Financial Results

WALTHAM, Mass., Nov. 10, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and operational results for the third quarter ended September 30, 2011.

Total revenue for the three months ended September 30, 2011 was $765,000, compared to $545,000 for the same period in the prior year. The increase was attributable to greater genetic test revenue.

Research and development expenses were $325,000 for the three months ended September 30, 2011, compared to $317,000 for the same period in the prior year. The Company continues its work in its weight management and periodontal disease programs.

Selling, general, and administrative expenses were $1.1 million for the three months ended September 30, 2011, compared to $1.2 million for the same period in the prior year. The decrease was primarily attributable to decreased corporate professional fees offset in part by increased patent-related legal fees and sales commissions paid to Amway.

The Company reported a net loss of $1.1 million, or $(0.03) per basic and diluted common share, for the third quarter of 2011, compared to a loss of $1.4 million, or $(0.04) per basic and diluted share, for the same period in the prior year. On September 30, 2011, the Company had cash and cash equivalents of $1.0 million and had $3.3 million available under its credit facility.

"We are pleased to show continued revenue growth for our Weight Management Genetic Test and Wellness Select combination products. Customers are now paying monthly or annual subscription fees to our premium weight management web-tools package," said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "In addition, enrollment in our clinical study to demonstrate the utility of using our PST® genetic test to improve the management of patients at risk of periodontal disease with Renaissance Health and the University of Michigan is proceeding with approximately 3,300 patients of the desired 4,000 enrolled thus far."  

Conference Call and Webcast InformationInterleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EST to review the Company's new business developments and second quarter financial results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast and replay access will be available on the Investors section of the Company's Website at:

About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit

Certain statements contained herein are "forward-looking" statementsBecause such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's  annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.Contacts:Interleukin Media:

Interleukin Investors:Jon Siegal / Kirsten Fallon

Eliot LurierSchwartz MSL

Interleukin Genetics, Inc.781-684-0770 INTERLEUKIN GENETICS, INC.FINANCIAL HIGHLIGHTSBalance Sheet Data : (Unaudited)September 30,December 31,20112010(Unaudited)Cash and cash equivalents

3,999,029Total current assets

4,752,790Total assets$
5,975,000Total current liabilities

,633,096Total liabilities$
2,633,096Total shareholders' deficit

(6,658,096)Total liabilities and shareholders' deficit

5,975,000Statement of Operations Data (Unaudited): Three Months Ended Sept. 30,Nine Months Ended Sept. 30,2011201020112010Revenue:Genetic testing service revenue

,460,601Other34,22213,59352,00825,805Total revenue765,416544,7442,281,7651,486,406Cost of revenue

370,740409,0101,166,7931,254,033Gross profit (loss)

394,676135,7341,114,972232,373Operating costs and expenses:Research and development

324,669317,155989,2871,059,450Selling, general and administrative

1,086,6061,168,3143,542,2034,209,879Amortization of intangibles

28,86328,86386,59086,590Total operating expenses

1,440,1381,514,3324,618,0805,355,919Loss from operations

(1,045,462)(1,378,598)(3,503,108)(5,123,546)Total other income and (expense), net

(89,080)(63,545)(257,778)(177,371)Loss from continuing operationsbefore income taxes

(1,134,542)(1,442,143)(3,760,886)(5,300,917)Income taxes----Loss from continuing operations

(5,300,917)Income from discontinued operations,net of  income taxes

-158,366482,530Net loss$
(4,818,387)Basic and diluted net (loss) income per common share from:Continuing operations

(0.15)Discontinued operations loss$
(0.14)Weighted average common shares outstanding,basic and diluted


SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics, Inc. Announces Conference Call to Discuss Third Quarter 2011 Results
2. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
3. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
4. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
5. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
6. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
7. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
8. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
9. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
10. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
11. Interleukin Genetics Reports Second Quarter 2009 Financial Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/25/2015)... Francisco, CA (PRWEB) , ... November 25, 2015 ... ... microbial genomics company uBiome, were featured on AngelList early in their initial angel ... launching an AngelList syndicate for individuals looking to make early stage investments in ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association ... 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award ... work with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):